Strategies In Pharmacoeconomics And Outcomes Research

Get a healthy perspective on pharmaceutical economics! Strategies in Pharmacoeconomics and Outcomes Research presents a comprehensive introduction to the economic aspects of the health sector, focusing on strategies for the development and marketing of healthcare products. A much-needed addition to this relatively new field, the book narrows health economics into the sub-discipline of pharmacoeconomics, bridging the gap between different interest groups in the pharmaceutical industry-research and development at one end, sales and marketing at the other. Using basic terminology and practical examples with descriptive tables and figures, it analyzes the implications of projecting costs of pharmaceutical products as a method of determining the viability of their development. Written from an international perspective, Strategies in Pharmacoeconomics and Outcomes Research examines the costs of drug therapy on health care systems and society through global marketing and modeling strategies, including clinical research and trial examples. Through the interlinked concepts of clinical research, outcomes research and pharmacoeconomics, the book evaluates the effectiveness of health technologies under “real world” circumstances or “normal” medical practice to achieve the optimum benefit from the resources available. The research process follows the economics of a drug?s efficacy (how it works under ideal circumstances) to its effectiveness (how it does in “real” life) to its efficiency (how cost-effective it is) in determining the baseline effects of a disease on economic and humanistic parameters. Strategies in Pharmacoeconomics and Outcomes Research also examines: resources and cost benefits (direct, indirect, intangible, and quality of life) health economical models (decision-tree analysis, Markov-model) reimbursement differences between countries due to the rate of currency exchange drug monitoring and regulation . . . and includes an extensive glossary! At a time when health economics has become increasingly important, Strategies in Pharmacoeconomics and Outcomes Research is an essential tool for the pharmaceutical, diagnostic, and medical device industries to ensure the most efficient use of limited resources. The book?s practical tone and common-sense methods provide a realistic approach that will benefit pharmaceutical and medical professionals, product managers, business development managers, drug regulatory affairs officials, and clinical study coordinators in making strategic and operational decisions about pharmaceutical development, production, or consumption.

Fully updated and substantially expanded, this second edition of the well-known ACCP publication will enable practicing pharmacists and pharmacy students to develop knowledge and skill to measure and evaluate economic and patient-based outcomes. Learn How to Measure and Evaluate Economic and Patient-based Outcomes

Understanding Health Outcomes and Pharmacoeconomics presents an overview of the tools used to assess patient-related health status including associated health outcomes and the analyses that are used to determine cost-effectiveness in evaluating pharmacotherapeutic interventions to improve health. Including data and examples from several different countries, this comprehensive text will help students understand the basis for decisions made at the local and governmental level that impact the use of pharmaceuticals and provide a strong foundation for understanding the principles used in cost-effective decision making. With commentaries, cases studies, and highlighting international differences, this text concludes with a discussion of the need for a universal system for documenting medication use. Understanding Health Outcomes and Pharmacoeconomics provides definitions of comparative effectiveness research (CER) and comparisons of pharmacoeconomic models (including cost-effectivess, cost-benefit, and cost utility analyses). This inclusive text provides describes how CER is linked to various pharmacoeconomic models by providing examples from clinical trials with comparative pharmacotherapy and cost parameters. From the Introduction: "The need for interprofessional education was made apparent in the 2003 Health Professions Education: A Bridge to Quality report. All healthcare professionals must be educated to deliver patient-centered care as members of an interprofessional team, emphasizing evidence-based practice, quality improvement approaches, and informatics. An enhanced understanding of pharmacoeconomic principles is a step in the right direction for healthcare practitioners as we do our best to ensure optimal medication therapy outcomes for patients and society at-large." -- George E. MacKinnon III, PhD, RPh, FASHP

A main purpose for an introductory textbook is to acquaint the reader with various methods and issues in pharmacoeconomic and outcomes research.

Designed as a true introduction to the subject, Essentials of Pharmacoeconomics: Health Economics and Outcomes Research, ThirdEdition includes information on fundamental topics, defines terminology, and provides examples for evaluating published research, making it perfect for any pharmacy student or practitioner new to the topic. This updated edition provides the critical foundations of knowledge for measuring costs and health-related quality-of-life (HRQoL) and evaluating the four types of studies (CMA, CEA, CUA, and CBA); it also explains Markov and Budget Impact Analysis modeling, and discusses the advantages and disadvantages of using retrospective databases and real-world data (RWD). Additionally, the text summarizes the use of pharmacoeconomic evaluations by decision makers outside of the United States and the extent to which pharmacoeconomic data are used to make decisions in the United States, includes barriers to its use, and discusses future issues. All of this information is designed to ensure preparedness to improve clinical and humanistic outcomes based on available resources.

From Pharmacoeconomics in Perspective: A Primer on Research, Techniques, and Information you will discover comprehensive explanations of principles in this sophisticated field through up-to-date research overviews, analysis types, research techniques, information evaluations. This unique book is primarily nonmathematical and highlights the qualitative details underpinning pharmacoeconomics for pharmacists and other medical professionals. This information is also a must for graduate students who need guidance through today's complicated pharmacy environment. Pharmacoeconomics in Perspective addresses a diverse yet increasingly growing slice of the healthcare environment where noneconomists are challenged to prepare, interpret, and use pharmacoeconomic information. This book provides you with the means to defend yourself against unscrupulous promotion of new drugs, unfounded conclusions in scientific literature, and research studies conducted with inaccurate methods. Pharmacoeconomics in Perspective provides charts, graphs, and figures to help you put all of its useful information into perspective. This invaluable book covers a broad range of topics within this subject area, including: pharmacoeconomics as outcomes research healthcare expenditures and pharmacoeconomics pharmacoeconomics within drug development types of pharmacoeconomic analysis, including cost of illness analysis, cost benefit analysis, cost effectiveness analysis, cost utility analysis, and cost minimization analysis techniques of pharmacoeconomics, including perspectives for research analysis, determination of outcomes measures, and categorization of pharmacoeconomic costs review of recent pharmacoeconomic research From this book, you will find that all medical treatments come with a cost and that once resources are used on one item, those same resources cannot be reused on another item; your choice has an opportunity cost. The new tools presented in Pharmacoeconomics in Perspective will assist you in making judgements and comparisons among treatment alternatives and help you make educated decisions about such important issues as what drugs to prescribe or from what company to buy prescription drugs.

In this era of finite budgets, healthcare rationing, medication shortages, and the global aging and burgeoning of populations, numerous stakeholders in the healthcare arena must understand the basic principles of pharmacoeconomics and how these may be correctly applied to facilitate drug development, rationing, patient segmentation, disease management, and pricing model development. Pharmacoeconomics: From Theory to Practice, Second Edition focuses on how to more efficiently and rationally leverage these healthcare resources, not by restricting access to necessary services, but by using them more efficiently. This updated volume arms decision makers with the tools they need to make wise choices in an area where the stakes are extremely high—the health of the global population. Key Features: Introduces the major concepts and principles of Pharmacoeconomics Gives updated information about pharmacoeconomic models, value-based pricing, novel modelling methodologies and international utilization of these modalities in government, the pharmaceutical industry, and health care settings Demonstrates the full range of ethical and moral issues, as well as overall public health and commercial concerns that are often involved in decisions entailing pharmacoeconomic issues Presents both theory and methodology discussions, including real-world examples, in each chapter 'The methods and application of pharmacoeconomics are rapidly evolving, so the new edition of this textbook is very timely. It provides an excellent introduction for those new to the field, whether they be students, professionals within the pharmaceutical industry, or health care professionals more generally. A particularly useful feature of the book is that it gives an introduction both to the main methods used in pharmacoeconomics studies and how these studies are used in decisions about the reimbursement or appropriate use of medicines in several countries.' - Michael Drummond, Professor of Health Economics, University of York